Toxicity to Tumors not to Patients
About EpicentRx
A Clinical Stage Immuno-Oncology Company
With a prolific platform of small molecule therapies, innate immune checkpoint inhibitors, cell based therapies, vaccines and oncolytic viruses, the central focus of EpicentRx Inc., a privately owned physician-led phase 3 clinical-stage immuno-oncology company located in San Diego, California, is on anticancer immunization and chemo/radioprotection of normal tissues. As a company of actively practicing oncologists/internists we at EpicentRx take cancer very very personally (in a literal and figurative sense) with the plight of the patient serving first and foremost as the motivation to customize or personalize our platform of immunotherapies both to individuals that are otherwise out of options and to groups of individuals with common and in many cases currently undruggable mutations.
For further information, please contact us.
RRx-001
As a “next generation” small molecule immunotherapeutic, RRx-001 stimulates both the innate and adaptive immune systems and can be used as monotherapy or as a combination partner for chemotherapy, immunotherapy, radiation and targeted agents.
PHASE 3 REPLATINUM
EpicentRx is currently enrolling patients with advanced small cell carcinoma to a Phase 3 clinical trial called REPLATINUM, investigating the activity and safety of RRx-001 in combination with platinum doublet chemotherapy versus platinum chemotherapy alone.
Custom Oncolytic Viruses
Multiple proprietary viral vectors with an almost unlimited number of transgene options have been developed to treat patients with multiple tumor types and mutations.
Personalized Viral Vaccines
The application of viruses engineered to express tumor antigens and immunostimulatory cytokines induce an immune response, which potentially leads to durable tumor rejection.
UPCOMING ABSTRACT SPEAKER PRESENTATIONS
March 29th – Apr 3rd, 2019. AACR Annual Meeting 2019. Atlanta, GA.
Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells
Feb 28th-Mar 2nd 2019, ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, CA.
RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
RECENTLY COMPLETED ABSTRACT PRESENTATIONS
Nov 15th-18th 2018, 23rd Annual Society for NeuroOncology (SNO) Meeting
Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Nov 7th-11th 2018, 33rd Society for Immunotherapy of Cancer (SITC) Annual Meeting
RRx-001 is a phase 3-ready small molecule which immunonormalizes the tumor microenvironment
Nov 7th-11th 2018, 33rd Society for Immunotherapy of Cancer (SITC) Annual Meeting
BETAMUNE, a replication competent type 5 adenovirus carrying a TGF-Beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
Oct 22nd 2018, 60th American Society for Radiation Oncology (ASTRO) Annual Meeting
Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases